Tau positron emission tomography imaging

Cold Spring Harbor Perspectives in Biology

Volumn 9, Issue 5, 2017, Pages

  Kolb, Hartmuth C ^a   Andrés, José Ignacio ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; DIAGNOSTIC IMAGING; HUMAN; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 85018730599     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a023721     Document Type: Review

References (80)

1. Alzforum. 2013. HAI—Spotlight on Tau Tracers at Human Amyloid Imaging Meeting. January 25. www.alzforum.org/news/conference-coverage/hai-spotlight-tau-tracershuman- amyloid-imaging-meeting?
2. Alzforum. 2015. Human Amyloid Imaging Meeting Was Abuzz with Talk of Tau. February 6. www.alzforum.org/news/conference-coverage/human-amyloid-imaging-mee ting-was-abuzz-talk-tau?
3. Anand R, Dip Gill K, Ali Mahdi A. 2014. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 76: 27–50.
4. Ariza M, Kolb HC, Moechars D, Rombouts F, Andrés JI. 2015. Tau positron emission tomography (PET) imaging: Past, present and future. J Med Chem 58: 4365–4382.
5. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42: 631–639.
6. Bakhti M, Aggarwal S, Simons M. 2014.Myelin architecture: Zippering membranes tightly together. Cell Mol Life Sci 71: 1265–1277.
7. Barrio JR, Huang SC, Cole G, Satyamurthy N, Petric A, Phelps ME, Small G. 1999. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Labelled Compd Radiopharm 42: S194–S195.
8. Borroni E, Gobbi L, Honer M, Knust H, Koerner M, Muri D. 2014. 2-Phenyl or 2-hetarylimidazo[1,2-a]pyridine derivatives. International Patent 2014. WO2014/177458 A1.
9. Braak H, Braak E. 1991. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
10. Cashion DK, Cheng G, Kasi D, Kolb HC. 2011. Imaging agents for detecting neurological disorders. International Patent 2011. WO 2011/119565 A1.
11. Chhatwal J, Johnson K. 2015. Human Amyloid Imaging Conference 2015. www.alzforum.org/print-series/390816.
12. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. 2013. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34: 457–468.
13. Chien D, Katrin A, Bahri S, Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, Su MY, Elizarov A, et al. 2014. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38: 171–184.
14. Citron M. 2010. Alzheimer’s disease: Strategies for disease modification. Nat Rev Drug Disc 9: 387–398.
15. Clavaguera F, Grueninger F, Tolnay M. 2014. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. Neuropharmacology 76: 9–15.
16. DeKosky ST, Marek K. 2003. Looking backward to move forward: Early detection of neurodegenerative disorders. Science 302: 830–834.
17. Delacourte A. 1998. Diagnosis of Alzheimer’s disease. Ann Biol Clin 56: 133–142.
18. Fargo K, Bleiler L. 2014. Alzheimer’s Association report. Alzheimers Dement 10: e47–e92.
19. 18F-THK-523: A novel in vivo tau imaging ligand for Alzheimer’s disease. Brain 134: 1089–1100.
20. Gobbi L, Knust H, Koblet A. 2014. Imidazo[2,1]thiazol-3- one derivatives useful as diagnostic agents for Alzheimer’s disease. International Patent 2014. WO2014/ 026881 A1.
21. Gobbi L, Knust H, Koerner M, Muri D. 2015a. Imidazo[1,2- a]pyridin-7-amines as imaging tools. International Patent 2015. WO2015/044095 A1.
22. Gobbi L, Knust H, Koerner M, Muri D. 2015b. Diazacarbazole derivatives as Tau-PET-ligands. International Patent 2015. WO2015/052105 A1.
23. Harada R, Okamura N, Furumoto S, Yoshikawa T, Arai H, Yanai K, Kudo Y. 2014. Use of a benzimidazole derivative BF-188 in fluorescence multispectral imaging for selective visualization of tau protein fibrils in the Alzheimer’s disease brain. Mol Imaging Biol 16: 19–27.
24. 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 55: 1532–1538.
25. Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N. 2014. Alternative approaches for PET radiotracer development in Alzheimers disease: Imaging beyond plaque. J Label Compd Radiopharm 57: 323–331.
26. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. 2007. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 28: 251–260.
27. Janke C, Beck M, Stahl T, Holzer M, Brauer K, Bigl V, Arendt T. 1999. Phylogenetic diversity of the expression of the microtubule-associated protein tau: Implications for neurodegenerative disorders. Mol Brain Res 68: 119–128.
28. Karran E, Mercken M, De Strooper B. 2011. The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Disc 10: 698–712.
29. Ke YD, Suchowerska AK, van der Hoven J, De Silva DM, Wu CW, van Eersel J, Ittner A, Ittner LM. 2012. Lessons from tau-deficient mice. Int J Alzheimers Dis 2012: 873270.
30. Khachaturian ZS. 1985. Diagnosis of Alzheimer’s disease. Arch Neurol 42: 1097–1105.
31. 18FT808 (AV-680). J Alzheimer’s Assoc 9: P844–P845.
32. Kung HF. 2012. The β-amyloid hypothesis in Alzheimer’s disease: Seeing is believing. ACS Med Chem Lett 3: 265-267.
33. Landau M, Sawaya MR, Faull KF, Laganowsky A, Jiang L, Sievers SA, Liu J, Barrio JR, Eisenberg D. 2011. Towards a pharmacophore for amyloid. PLoS Biol 9: e1001080.
34. Lei Y, Yu L, Zhou B, Zhu C, Wen Z, Lin SH. 2014. Landscapes of four-enantiomer conical intersections for photoiso- merization of stilbene: CASSCF calculation. J Phys Chem A 118: 9021–9031.
35. Lemoine L, Saint-Aubert L, Marutle A, Antoni G, Eriksson JP, Ghetti B, Okamura N, Nennesmo I, Gillberg PG, Nordberg A. 2015. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun 3: 40.
36. Maccioni RB, Farías G, Morales I, Navarrete L. 2010. The revitalized tau hypothesis on Alzheimer’s disease. Arch Med Res 41: 226–231.
37. Mach RH. 2014. New targets for the development of PET tracers for imaging neurodegeneration in Alzheimer disease. J Nucl Med 55: 1221–1224.
38. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VMY, Ono M, et al. 2013. Imaging of tau pathology in mouse model and in Alzheimer patients compared to normal controls. Neuron 79: 1094–1108.
39. Mason NS, Mathis CA, Klunk WE. 2013. Positron emission tomography radioligands for in vivo imaging of Ab plaques. J Label Compd Radiopharm 56: 89–95.
40. Matsumura K, Ono M, Hayashi S, Kimura H, Okamoto Y, Ihara M, Takahashi R, Moric H, Saji H. 2011. Phenyldiazenyl benzothiazole derivatives as probes for in vivo imaging of neurofibrillary tangles in Alzheimer’s disease brains. Med Chem Commun 2: 596–600.
41. 18F-Labeled phenyldiazenyl benzothiazole for in vivo imaging of neurofibrillary tangles in Alzheimer’s disease brains. ACS Med Chem Lett 3: 58–62.
42. Matthews PM, Rabiner EA, Passchier J, Gunn RN. 2011. Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 73: 175–186.
43. 18F-T807 imaging in a case of nonfluent variant primary progressive aphasia. J Alzheimer’s Assoc 11: P791–P792.
44. Medeiros R, Baglietto-Vargas D, LaFerla FM. 2011. The role of tau in Alzheimer’s disease and related disorders. CNS Neurosci Ther 17: 514–524.
45. Mintun M, Schwarz A, Joshi A, Shcherbinin S, Chien D, Elizarov A, Su MY, Shankle W, Pontecorvo M, Tauscher J, et al. 2013. Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to AD. Alzheimers Dement 9: P842.
46. Nelson LD, Siddarth P, Kepe V, Scheibel KE, Huang SC, Barrio JR, Small GW. 2011. Positron emission tomography of brain β-amyloid and tau levels in adults with Down syndrome. Arch Neurol 68: 768–774.
47. Noël S, Cadet S, Gras E, Hureau C. 2013. The benzazole scaffold: A SWAT to combat Alzheimer’s disease. Chem Soc Rev 42: 7747–7762.
48. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, Yamamoto T, Fujiwara H, Nemoto M, Maruyama M, et al. 2005. Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci 25: 10857-10862.
49. 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54: 1420–1427.
50. Okamura N, Harada R, Furumoto S, Arai H, Yanai K, Kudo Y. 2014a. Tau PET imaging in Alzheimer’s disease. Curr Neurol Neurosci Rep 14: 500.
51. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, et al. 2014b. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137: 1762–1771.
52. 18F-THK-5351, a novel PET tracer for imaging tau pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41: S260.
53. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O’Neil JP, Janabi M, Lazaris A, Cantwell A, et al. 2016. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139: 1551–1567.
54. Piel M, Vernaleken I, Rösch F. 2014. Positron emission tomography in CNS drug discovery and drug monitoring. J Med Chem 57: 9232–9258.
55. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaeggi F, Wolburg H, Gengler S, et al. 2006. Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940–946.
56. Ramachandran G, Udgaonkar JB. 2013.Mechanistic studies unravel the complexity inherent in tau aggregation leading to Alzheimer’s disease and the tauopathies. Biochemistry 52: 4107–4126.
57. Reiman EM, Jagust WJ. 2012. Brain imaging in the study of Alzheimer’s disease. Neuroimage 61: 505–516.
58. Rowe CC, Villemagne VL. 2013. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin North Am 97: 377–398.
59. Shah M, Catafau AM. 2014.Molecular imaging insights into neurodegeneration: Focus on tau PETradiotracers. JNucl Med 55: 871–874.
60. Shin J, Kepe V, Barrio JR, Small GW. 2011. The merits of FDDNP-PET imaging in Alzheimer’s disease. J Alzheimers Dis 26: 135–145.
61. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, et al. 2006. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355: 2652–2663.
62. Small GW, Kepe V, Siddarth P, Ercoli LM, Merrill DA, Donoghue N, Bookheimer SY, Martinez J, Omalu B, Bailes J, et al. 2013. PET scanning of brain tau in retired National Football League players: Preliminary findings. Am J Geriatr Psychiatry 21: 138–144.
63. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. 2011. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Associationworkgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7: 280–292.
64. Spillantini MG, Goedert M. 2013. Tau pathology and neurodegeneration. Lancet Neurol 12: 609–622.
65. Stephens A. 2015. Novel tau PET tracers: Characterization and development. ADPD Imaging Satellite Symposium. Nice, France.
66. Szardenings AK, Kolb HC, Walsh JC, Chen G, Gangadharmath UB, Kasi D, Liu C, Sinha A, Wang E, Yu C, et al. 2012. Imaging agents for detecting neurological dysfunction. International Patent 2012. US 2012/0302755 A1.
67. Taghavi A, Nasir S, Pickhardt M, Heyny-von Haussen R, Mall G, Mandelkow E, Mandelkow EM, Schmidt B. 2011. N-Benzylidene-benzohydrazides as novel and selective tau-PHF ligands. J Alzheimers Dis 27: 835–843.
68. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, Shipley NJ, Libri V, Lockhart A. 2009. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies. J Neurochem 109: 623–630.
69. Trojanowski JQ, Clark CM, Schmidt ML, Arnold SE, Lee VM. 1997. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer’s disease. Neurobiol Aging 18: S75–S79.
70. Valk PE, Bailey DL, Townsend DW, Maisey MN. 2005. Positron emission tomography: Basic science. Springer, New York.
71. Villemagne VL, Okamura N. 2014. In vivo tau imaging: Obstacles and progress. Alzheimers Dement 10: S254-S264.
72. Villemagne VL, Furumoto S, Fodero-Tavoletti M, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N. 2012. The challenges of tau imaging. Future Neurol 7: 409–421.
73. Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Doré V, et al. 2014. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging 41: 816–826.
74. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. 2015. Tau imaging: Early progress and future directions. Lancet Neurol 14: 114–124.
75. Waldeck DH. 1991. Photoisomerization dynamics of stilbene. Chem Rev 91: 415–436.
76. Wegmann S, Jung YJ, Chinnathambi S, Mandelkow EM, Mandelkow E, Muller DJ. 2010. Human tau isoforms assemble into ribbon-like fibrils that display polymorphic structure and stability. J Biol Chem 285: 27302-27313.
77. 18F-T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement 9: 666–676.
78. Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, et al. 2012.A highly selective and specific PET tracer for imaging of tau pathologies. J. Alzheimers Dis 31: 601–612.
79. Zhou M, Wang X, Liu Z, Yu L, Hu S, Chen L, Zeng W. 2014. Advances of molecular imaging probes for the diagnosis of Alzheimer’s disease. Curr Alzheimer Res 11: 221–231.
80. Zimmer ER, Leuzy A, Gauthier S, Rosa-Neto P. 2014. Developments in tau PET imaging. Can J Neurol Sci 41: 547–553.